nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCB1—Mitomycin—urinary bladder cancer	0.0957	0.16	CbGbCtD
Canagliflozin—ABCC2—Carboplatin—urinary bladder cancer	0.0719	0.12	CbGbCtD
Canagliflozin—ABCC2—Cisplatin—urinary bladder cancer	0.0614	0.103	CbGbCtD
Canagliflozin—ABCC2—Etoposide—urinary bladder cancer	0.0603	0.101	CbGbCtD
Canagliflozin—ALB—Fluorouracil—urinary bladder cancer	0.0451	0.0754	CbGbCtD
Canagliflozin—CYP3A4—Thiotepa—urinary bladder cancer	0.0435	0.0728	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—urinary bladder cancer	0.0412	0.0689	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—urinary bladder cancer	0.0399	0.0668	CbGbCtD
Canagliflozin—SLC5A2—urine—urinary bladder cancer	0.0327	0.333	CbGeAlD
Canagliflozin—ABCB1—Gemcitabine—urinary bladder cancer	0.0276	0.0461	CbGbCtD
Canagliflozin—ALB—Methotrexate—urinary bladder cancer	0.0248	0.0416	CbGbCtD
Canagliflozin—ABCB1—Cisplatin—urinary bladder cancer	0.02	0.0335	CbGbCtD
Canagliflozin—ABCB1—Etoposide—urinary bladder cancer	0.0197	0.0329	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—urinary bladder cancer	0.0134	0.0225	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—urinary bladder cancer	0.013	0.0218	CbGbCtD
Canagliflozin—CYP3A4—Etoposide—urinary bladder cancer	0.0118	0.0197	CbGbCtD
Canagliflozin—Dapagliflozin—UGT2B7—urinary bladder cancer	0.0101	1	CrCbGaD
Canagliflozin—SLC5A1—prostate gland—urinary bladder cancer	0.00889	0.0906	CbGeAlD
Canagliflozin—CYP3A4—Doxorubicin—urinary bladder cancer	0.00804	0.0135	CbGbCtD
Canagliflozin—SLC5A2—renal system—urinary bladder cancer	0.00799	0.0815	CbGeAlD
Canagliflozin—SLC5A1—epithelium—urinary bladder cancer	0.00653	0.0665	CbGeAlD
Canagliflozin—SLC5A1—renal system—urinary bladder cancer	0.00606	0.0617	CbGeAlD
Canagliflozin—SLC5A2—vagina—urinary bladder cancer	0.00579	0.059	CbGeAlD
Canagliflozin—SLC5A1—vagina—urinary bladder cancer	0.00439	0.0447	CbGeAlD
Canagliflozin—UGT1A9—renal system—urinary bladder cancer	0.00381	0.0389	CbGeAlD
Canagliflozin—CYP3A4—urine—urinary bladder cancer	0.00342	0.0349	CbGeAlD
Canagliflozin—ORM1—prostate gland—urinary bladder cancer	0.00294	0.03	CbGeAlD
Canagliflozin—ABCC2—prostate gland—urinary bladder cancer	0.00242	0.0246	CbGeAlD
Canagliflozin—ABCC2—renal system—urinary bladder cancer	0.00165	0.0168	CbGeAlD
Canagliflozin—ORM1—female reproductive system—urinary bladder cancer	0.00161	0.0164	CbGeAlD
Canagliflozin—ABCC2—female reproductive system—urinary bladder cancer	0.00132	0.0135	CbGeAlD
Canagliflozin—ORM1—lymph node—urinary bladder cancer	0.00094	0.00958	CbGeAlD
Canagliflozin—ABCB1—prostate gland—urinary bladder cancer	0.00087	0.00886	CbGeAlD
Canagliflozin—CYP3A4—renal system—urinary bladder cancer	0.000837	0.00853	CbGeAlD
Canagliflozin—ALB—lymph node—urinary bladder cancer	0.000824	0.0084	CbGeAlD
Canagliflozin—Blood creatinine increased—Thiotepa—urinary bladder cancer	0.000786	0.00586	CcSEcCtD
Canagliflozin—Dehydration—Thiotepa—urinary bladder cancer	0.00078	0.00581	CcSEcCtD
Canagliflozin—ABCC2—lymph node—urinary bladder cancer	0.000772	0.00787	CbGeAlD
Canagliflozin—Serum creatinine increased—Epirubicin—urinary bladder cancer	0.000756	0.00564	CcSEcCtD
Canagliflozin—Rash maculo-papular—Etoposide—urinary bladder cancer	0.000754	0.00562	CcSEcCtD
Canagliflozin—Rash—Valrubicin—urinary bladder cancer	0.00075	0.00559	CcSEcCtD
Canagliflozin—Dermatitis—Valrubicin—urinary bladder cancer	0.000749	0.00559	CcSEcCtD
Canagliflozin—Polyuria—Cisplatin—urinary bladder cancer	0.000749	0.00558	CcSEcCtD
Canagliflozin—ABCB1—seminal vesicle—urinary bladder cancer	0.000735	0.0075	CbGeAlD
Canagliflozin—Renal failure acute—Cisplatin—urinary bladder cancer	0.000712	0.00531	CcSEcCtD
Canagliflozin—Nausea—Valrubicin—urinary bladder cancer	0.000707	0.00527	CcSEcCtD
Canagliflozin—Fatigue—Mitomycin—urinary bladder cancer	0.000707	0.00527	CcSEcCtD
Canagliflozin—Serum creatinine increased—Doxorubicin—urinary bladder cancer	0.0007	0.00522	CcSEcCtD
Canagliflozin—CYP3A4—female reproductive system—urinary bladder cancer	0.000671	0.00683	CbGeAlD
Canagliflozin—Blood creatinine increased—Gemcitabine—urinary bladder cancer	0.000661	0.00493	CcSEcCtD
Canagliflozin—ABCB1—epithelium—urinary bladder cancer	0.000639	0.00651	CbGeAlD
Canagliflozin—Blood creatinine increased—Cisplatin—urinary bladder cancer	0.000616	0.00459	CcSEcCtD
Canagliflozin—Dehydration—Cisplatin—urinary bladder cancer	0.000611	0.00456	CcSEcCtD
Canagliflozin—Rash erythematous—Epirubicin—urinary bladder cancer	0.000607	0.00453	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Cisplatin—urinary bladder cancer	0.0006	0.00448	CcSEcCtD
Canagliflozin—Breast disorder—Cisplatin—urinary bladder cancer	0.000594	0.00443	CcSEcCtD
Canagliflozin—ABCB1—renal system—urinary bladder cancer	0.000593	0.00604	CbGeAlD
Canagliflozin—Asthenia—Mitomycin—urinary bladder cancer	0.000588	0.00438	CcSEcCtD
Canagliflozin—Rash pustular—Epirubicin—urinary bladder cancer	0.000583	0.00435	CcSEcCtD
Canagliflozin—ABCB1—urethra—urinary bladder cancer	0.000582	0.00593	CbGeAlD
Canagliflozin—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000573	0.00427	CcSEcCtD
Canagliflozin—Urethral disorder—Thiotepa—urinary bladder cancer	0.000569	0.00424	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—urinary bladder cancer	0.000562	0.00419	CcSEcCtD
Canagliflozin—Pancreatitis—Cisplatin—urinary bladder cancer	0.000557	0.00415	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.000547	0.00408	CcSEcCtD
Canagliflozin—Dizziness—Mitomycin—urinary bladder cancer	0.000542	0.00404	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—urinary bladder cancer	0.00054	0.00402	CcSEcCtD
Canagliflozin—Angiopathy—Thiotepa—urinary bladder cancer	0.000526	0.00392	CcSEcCtD
Canagliflozin—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00052	0.00387	CcSEcCtD
Canagliflozin—Rash—Mitomycin—urinary bladder cancer	0.000517	0.00385	CcSEcCtD
Canagliflozin—Dermatitis—Mitomycin—urinary bladder cancer	0.000516	0.00385	CcSEcCtD
Canagliflozin—Malnutrition—Thiotepa—urinary bladder cancer	0.000505	0.00377	CcSEcCtD
Canagliflozin—Erythema—Thiotepa—urinary bladder cancer	0.000505	0.00377	CcSEcCtD
Canagliflozin—Nocturia—Epirubicin—urinary bladder cancer	0.000501	0.00374	CcSEcCtD
Canagliflozin—Nausea—Mitomycin—urinary bladder cancer	0.000487	0.00363	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—urinary bladder cancer	0.000485	0.00362	CcSEcCtD
Canagliflozin—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000482	0.00359	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—urinary bladder cancer	0.00048	0.00358	CcSEcCtD
Canagliflozin—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000478	0.00357	CcSEcCtD
Canagliflozin—ABCB1—female reproductive system—urinary bladder cancer	0.000475	0.00484	CbGeAlD
Canagliflozin—Vaginal infection—Methotrexate—urinary bladder cancer	0.000469	0.0035	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—urinary bladder cancer	0.000464	0.00346	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—urinary bladder cancer	0.000457	0.00341	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—urinary bladder cancer	0.000454	0.00339	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—urinary bladder cancer	0.000449	0.00335	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—urinary bladder cancer	0.000449	0.00335	CcSEcCtD
Canagliflozin—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000449	0.00335	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—urinary bladder cancer	0.000449	0.00335	CcSEcCtD
Canagliflozin—Urethral disorder—Cisplatin—urinary bladder cancer	0.000446	0.00332	CcSEcCtD
Canagliflozin—Angiopathy—Gemcitabine—urinary bladder cancer	0.000443	0.0033	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—urinary bladder cancer	0.000439	0.00327	CcSEcCtD
Canagliflozin—Vaginal infection—Epirubicin—urinary bladder cancer	0.000439	0.00327	CcSEcCtD
Canagliflozin—Convulsion—Thiotepa—urinary bladder cancer	0.000438	0.00326	CcSEcCtD
Canagliflozin—ABCB1—vagina—urinary bladder cancer	0.000429	0.00438	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000427	0.00318	CcSEcCtD
Canagliflozin—Erythema—Gemcitabine—urinary bladder cancer	0.000425	0.00317	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—urinary bladder cancer	0.000423	0.00315	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—urinary bladder cancer	0.000423	0.00315	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—urinary bladder cancer	0.000421	0.00314	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—urinary bladder cancer	0.00042	0.00313	CcSEcCtD
Canagliflozin—Erythema—Fluorouracil—urinary bladder cancer	0.000418	0.00311	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—urinary bladder cancer	0.000416	0.0031	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000415	0.00309	CcSEcCtD
Canagliflozin—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000411	0.00307	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—urinary bladder cancer	0.000411	0.00306	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—urinary bladder cancer	0.000411	0.00306	CcSEcCtD
Canagliflozin—Infection—Thiotepa—urinary bladder cancer	0.000409	0.00305	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—urinary bladder cancer	0.000408	0.00305	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—urinary bladder cancer	0.000406	0.00303	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—urinary bladder cancer	0.000406	0.00303	CcSEcCtD
Canagliflozin—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000404	0.00301	CcSEcCtD
Canagliflozin—Skin disorder—Thiotepa—urinary bladder cancer	0.0004	0.00298	CcSEcCtD
Canagliflozin—Erythema—Cisplatin—urinary bladder cancer	0.000396	0.00295	CcSEcCtD
Canagliflozin—Malnutrition—Cisplatin—urinary bladder cancer	0.000396	0.00295	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.000391	0.00292	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—urinary bladder cancer	0.000391	0.00291	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—urinary bladder cancer	0.000389	0.0029	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000388	0.00289	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—urinary bladder cancer	0.000385	0.00287	CcSEcCtD
Canagliflozin—Angiopathy—Etoposide—urinary bladder cancer	0.000378	0.00282	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—urinary bladder cancer	0.000366	0.00273	CcSEcCtD
Canagliflozin—Convulsion—Fluorouracil—urinary bladder cancer	0.000362	0.0027	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000359	0.00268	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000359	0.00268	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000356	0.00265	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000356	0.00265	CcSEcCtD
Canagliflozin—Fatigue—Thiotepa—urinary bladder cancer	0.000355	0.00265	CcSEcCtD
Canagliflozin—Constipation—Thiotepa—urinary bladder cancer	0.000352	0.00263	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000346	0.00258	CcSEcCtD
Canagliflozin—Infection—Gemcitabine—urinary bladder cancer	0.000344	0.00257	CcSEcCtD
Canagliflozin—Convulsion—Cisplatin—urinary bladder cancer	0.000343	0.00256	CcSEcCtD
Canagliflozin—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00034	0.00254	CcSEcCtD
Canagliflozin—Infection—Fluorouracil—urinary bladder cancer	0.000339	0.00253	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000338	0.00252	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000337	0.00251	CcSEcCtD
Canagliflozin—Skin disorder—Gemcitabine—urinary bladder cancer	0.000337	0.00251	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000335	0.0025	CcSEcCtD
Canagliflozin—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000334	0.00249	CcSEcCtD
Canagliflozin—Urticaria—Thiotepa—urinary bladder cancer	0.000327	0.00244	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—urinary bladder cancer	0.000326	0.00243	CcSEcCtD
Canagliflozin—Abdominal pain—Thiotepa—urinary bladder cancer	0.000326	0.00243	CcSEcCtD
Canagliflozin—Hypotension—Gemcitabine—urinary bladder cancer	0.000324	0.00242	CcSEcCtD
Canagliflozin—Infection—Cisplatin—urinary bladder cancer	0.000321	0.00239	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00032	0.00239	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—urinary bladder cancer	0.000319	0.00238	CcSEcCtD
Canagliflozin—Hypotension—Fluorouracil—urinary bladder cancer	0.000319	0.00238	CcSEcCtD
Canagliflozin—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000317	0.00236	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000316	0.00236	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—urinary bladder cancer	0.000314	0.00234	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—urinary bladder cancer	0.000314	0.00234	CcSEcCtD
Canagliflozin—Skin disorder—Cisplatin—urinary bladder cancer	0.000314	0.00234	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000308	0.0023	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000307	0.00229	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—urinary bladder cancer	0.000306	0.00228	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—urinary bladder cancer	0.000305	0.00228	CcSEcCtD
Canagliflozin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000304	0.00226	CcSEcCtD
Canagliflozin—Hypotension—Cisplatin—urinary bladder cancer	0.000302	0.00225	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000299	0.00223	CcSEcCtD
Canagliflozin—Fatigue—Gemcitabine—urinary bladder cancer	0.000299	0.00223	CcSEcCtD
Canagliflozin—Constipation—Gemcitabine—urinary bladder cancer	0.000296	0.00221	CcSEcCtD
Canagliflozin—Asthenia—Thiotepa—urinary bladder cancer	0.000296	0.0022	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000294	0.00219	CcSEcCtD
Canagliflozin—Infection—Etoposide—urinary bladder cancer	0.000294	0.00219	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000293	0.00218	CcSEcCtD
Canagliflozin—Pruritus—Thiotepa—urinary bladder cancer	0.000292	0.00217	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—urinary bladder cancer	0.000291	0.00217	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—urinary bladder cancer	0.000288	0.00214	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—urinary bladder cancer	0.000286	0.00213	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000285	0.00213	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000285	0.00212	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—urinary bladder cancer	0.000282	0.00211	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000279	0.00208	CcSEcCtD
Canagliflozin—ABCB1—lymph node—urinary bladder cancer	0.000278	0.00283	CbGeAlD
Canagliflozin—Hypotension—Etoposide—urinary bladder cancer	0.000277	0.00206	CcSEcCtD
Canagliflozin—Dizziness—Thiotepa—urinary bladder cancer	0.000273	0.00203	CcSEcCtD
Canagliflozin—Urticaria—Fluorouracil—urinary bladder cancer	0.000271	0.00202	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—urinary bladder cancer	0.00027	0.00201	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000266	0.00199	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000265	0.00197	CcSEcCtD
Canagliflozin—Rash—Thiotepa—urinary bladder cancer	0.00026	0.00194	CcSEcCtD
Canagliflozin—Dermatitis—Thiotepa—urinary bladder cancer	0.00026	0.00194	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000256	0.00191	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—urinary bladder cancer	0.000255	0.0019	CcSEcCtD
Canagliflozin—Constipation—Etoposide—urinary bladder cancer	0.000253	0.00189	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000253	0.00189	CcSEcCtD
Canagliflozin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000251	0.00187	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000249	0.00186	CcSEcCtD
Canagliflozin—Asthenia—Gemcitabine—urinary bladder cancer	0.000249	0.00185	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000246	0.00184	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000246	0.00184	CcSEcCtD
Canagliflozin—Pruritus—Gemcitabine—urinary bladder cancer	0.000245	0.00183	CcSEcCtD
Canagliflozin—Nausea—Thiotepa—urinary bladder cancer	0.000245	0.00183	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—urinary bladder cancer	0.000245	0.00182	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000242	0.00181	CcSEcCtD
Canagliflozin—Pruritus—Fluorouracil—urinary bladder cancer	0.000241	0.0018	CcSEcCtD
Canagliflozin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000238	0.00178	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—urinary bladder cancer	0.000235	0.00175	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—urinary bladder cancer	0.000234	0.00175	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000234	0.00174	CcSEcCtD
Canagliflozin—Asthenia—Cisplatin—urinary bladder cancer	0.000232	0.00173	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000231	0.00172	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—urinary bladder cancer	0.000229	0.00171	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—urinary bladder cancer	0.000226	0.00169	CcSEcCtD
Canagliflozin—Dizziness—Fluorouracil—urinary bladder cancer	0.000225	0.00168	CcSEcCtD
Canagliflozin—Rash—Gemcitabine—urinary bladder cancer	0.000219	0.00163	CcSEcCtD
Canagliflozin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000218	0.00163	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000218	0.00163	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—urinary bladder cancer	0.000217	0.00162	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—urinary bladder cancer	0.000217	0.00162	CcSEcCtD
Canagliflozin—Rash—Fluorouracil—urinary bladder cancer	0.000215	0.0016	CcSEcCtD
Canagliflozin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000215	0.0016	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000213	0.00159	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—urinary bladder cancer	0.000212	0.00158	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—urinary bladder cancer	0.000212	0.00158	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000212	0.00158	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—urinary bladder cancer	0.000209	0.00156	CcSEcCtD
Canagliflozin—Nausea—Gemcitabine—urinary bladder cancer	0.000206	0.00154	CcSEcCtD
Canagliflozin—Rash—Cisplatin—urinary bladder cancer	0.000204	0.00152	CcSEcCtD
Canagliflozin—Dermatitis—Cisplatin—urinary bladder cancer	0.000204	0.00152	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—urinary bladder cancer	0.000203	0.00152	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—urinary bladder cancer	0.000203	0.00152	CcSEcCtD
Canagliflozin—Nausea—Fluorouracil—urinary bladder cancer	0.000202	0.00151	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000196	0.00146	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—urinary bladder cancer	0.000196	0.00146	CcSEcCtD
Canagliflozin—Nausea—Cisplatin—urinary bladder cancer	0.000192	0.00143	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—urinary bladder cancer	0.000188	0.0014	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—urinary bladder cancer	0.000188	0.0014	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—urinary bladder cancer	0.000188	0.0014	CcSEcCtD
Canagliflozin—Rash—Etoposide—urinary bladder cancer	0.000187	0.00139	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—urinary bladder cancer	0.000186	0.00139	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000184	0.00137	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—urinary bladder cancer	0.000182	0.00136	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000179	0.00133	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—urinary bladder cancer	0.000176	0.00131	CcSEcCtD
Canagliflozin—Infection—Methotrexate—urinary bladder cancer	0.000176	0.00131	CcSEcCtD
Canagliflozin—Nausea—Etoposide—urinary bladder cancer	0.000176	0.00131	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000174	0.0013	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—urinary bladder cancer	0.000172	0.00128	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000172	0.00128	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—urinary bladder cancer	0.000169	0.00126	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—urinary bladder cancer	0.000169	0.00126	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—urinary bladder cancer	0.000166	0.00124	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000165	0.00123	CcSEcCtD
Canagliflozin—Infection—Epirubicin—urinary bladder cancer	0.000165	0.00123	CcSEcCtD
Canagliflozin—Shock—Epirubicin—urinary bladder cancer	0.000163	0.00122	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—urinary bladder cancer	0.000163	0.00122	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000163	0.00121	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—urinary bladder cancer	0.000161	0.0012	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000159	0.00119	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000157	0.00117	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—urinary bladder cancer	0.000155	0.00116	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000153	0.00114	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—urinary bladder cancer	0.000153	0.00114	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—urinary bladder cancer	0.000153	0.00114	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—urinary bladder cancer	0.000151	0.00113	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000151	0.00112	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000149	0.00111	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000145	0.00108	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—urinary bladder cancer	0.000143	0.00107	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000143	0.00107	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—urinary bladder cancer	0.000143	0.00107	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—urinary bladder cancer	0.000142	0.00106	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—urinary bladder cancer	0.000141	0.00105	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—urinary bladder cancer	0.00014	0.00105	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000136	0.00101	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000133	0.000988	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—urinary bladder cancer	0.000132	0.000987	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—urinary bladder cancer	0.000132	0.000983	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—urinary bladder cancer	0.000131	0.000979	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—urinary bladder cancer	0.000131	0.000978	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000131	0.000974	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—urinary bladder cancer	0.000127	0.000949	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000126	0.000936	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—urinary bladder cancer	0.000125	0.000935	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000122	0.000912	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—urinary bladder cancer	0.000122	0.00091	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000121	0.000905	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—urinary bladder cancer	0.000119	0.000888	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—urinary bladder cancer	0.000117	0.000875	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—urinary bladder cancer	0.000117	0.000874	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000113	0.000844	CcSEcCtD
Canagliflozin—Rash—Methotrexate—urinary bladder cancer	0.000112	0.000834	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—urinary bladder cancer	0.000112	0.000833	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—urinary bladder cancer	0.00011	0.000821	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—urinary bladder cancer	0.00011	0.000818	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—urinary bladder cancer	0.000109	0.00081	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—urinary bladder cancer	0.000105	0.000785	CcSEcCtD
Canagliflozin—Rash—Epirubicin—urinary bladder cancer	0.000105	0.00078	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—urinary bladder cancer	0.000105	0.000779	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—urinary bladder cancer	0.000102	0.000757	CcSEcCtD
Canagliflozin—SLC5A1—Disease—MTHFR—urinary bladder cancer	9.89e-05	0.000616	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TERT—urinary bladder cancer	9.87e-05	0.000615	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TERT—urinary bladder cancer	9.87e-05	0.000615	CbGpPWpGaD
Canagliflozin—Nausea—Epirubicin—urinary bladder cancer	9.86e-05	0.000735	CcSEcCtD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	9.8e-05	0.00061	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.74e-05	0.000606	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	9.7e-05	0.000604	CbGpPWpGaD
Canagliflozin—Rash—Doxorubicin—urinary bladder cancer	9.68e-05	0.000722	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—urinary bladder cancer	9.67e-05	0.000721	CcSEcCtD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	9.58e-05	0.000597	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TYMS—urinary bladder cancer	9.48e-05	0.000591	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TYMS—urinary bladder cancer	9.48e-05	0.000591	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NQO1—urinary bladder cancer	9.44e-05	0.000588	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NCOR1—urinary bladder cancer	9.37e-05	0.000584	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NCOR1—urinary bladder cancer	9.37e-05	0.000584	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTM1—urinary bladder cancer	9.37e-05	0.000584	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTM1—urinary bladder cancer	9.37e-05	0.000584	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL2—urinary bladder cancer	9.22e-05	0.000574	CbGpPWpGaD
Canagliflozin—Nausea—Doxorubicin—urinary bladder cancer	9.12e-05	0.00068	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—UGT2B7—urinary bladder cancer	9.05e-05	0.000564	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—FGFR3—urinary bladder cancer	9.05e-05	0.000564	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—FGFR3—urinary bladder cancer	9.05e-05	0.000564	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GPX1—urinary bladder cancer	8.98e-05	0.000559	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GPX1—urinary bladder cancer	8.98e-05	0.000559	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	8.96e-05	0.000558	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	8.84e-05	0.000551	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ERCC2—urinary bladder cancer	8.81e-05	0.000549	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ERCC2—urinary bladder cancer	8.81e-05	0.000549	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	8.56e-05	0.000533	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—MTHFR—urinary bladder cancer	8.29e-05	0.000516	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—MTHFR—urinary bladder cancer	8.29e-05	0.000516	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	8.26e-05	0.000514	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.21e-05	0.000511	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP4B1—urinary bladder cancer	8.15e-05	0.000508	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	8.02e-05	0.000499	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8e-05	0.000498	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	7.9e-05	0.000492	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTP1—urinary bladder cancer	7.88e-05	0.000491	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CREBBP—urinary bladder cancer	7.71e-05	0.00048	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CREBBP—urinary bladder cancer	7.71e-05	0.00048	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC19A1—urinary bladder cancer	7.7e-05	0.00048	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PRSS3—urinary bladder cancer	7.5e-05	0.000467	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TYMS—urinary bladder cancer	7.32e-05	0.000456	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	7.32e-05	0.000456	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	7.25e-05	0.000452	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NCOR1—urinary bladder cancer	7.24e-05	0.000451	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTM1—urinary bladder cancer	7.24e-05	0.000451	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	7.17e-05	0.000446	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	7.08e-05	0.000441	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.01e-05	0.000437	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	7e-05	0.000436	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RHOA—urinary bladder cancer	6.97e-05	0.000434	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—RHOA—urinary bladder cancer	6.97e-05	0.000434	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	6.95e-05	0.000433	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GPX1—urinary bladder cancer	6.93e-05	0.000432	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	6.81e-05	0.000424	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ERCC2—urinary bladder cancer	6.81e-05	0.000424	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPARG—urinary bladder cancer	6.72e-05	0.000418	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPARG—urinary bladder cancer	6.72e-05	0.000418	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—urinary bladder cancer	6.72e-05	0.000418	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	6.69e-05	0.000416	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.52e-05	0.000406	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CREBBP—urinary bladder cancer	6.45e-05	0.000402	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CREBBP—urinary bladder cancer	6.45e-05	0.000402	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB2—urinary bladder cancer	6.45e-05	0.000402	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB2—urinary bladder cancer	6.45e-05	0.000402	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—MTHFR—urinary bladder cancer	6.4e-05	0.000398	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—urinary bladder cancer	6.31e-05	0.000393	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—urinary bladder cancer	6.31e-05	0.000393	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.02e-05	0.000375	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMP—urinary bladder cancer	6e-05	0.000374	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5.92e-05	0.000369	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—urinary bladder cancer	5.92e-05	0.000369	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.76e-05	0.000359	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.71e-05	0.000356	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1A—urinary bladder cancer	5.52e-05	0.000344	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1A—urinary bladder cancer	5.52e-05	0.000344	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTEN—urinary bladder cancer	5.5e-05	0.000343	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTEN—urinary bladder cancer	5.5e-05	0.000343	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTZ1—urinary bladder cancer	5.47e-05	0.000341	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NAT2—urinary bladder cancer	5.42e-05	0.000338	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	5.34e-05	0.000332	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—urinary bladder cancer	5.29e-05	0.000329	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—urinary bladder cancer	5.29e-05	0.000329	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EP300—urinary bladder cancer	5.25e-05	0.000327	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EP300—urinary bladder cancer	5.25e-05	0.000327	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	5.23e-05	0.000326	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	5.21e-05	0.000325	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	5.19e-05	0.000323	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—urinary bladder cancer	5.19e-05	0.000323	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTO2—urinary bladder cancer	5.18e-05	0.000323	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAT1—urinary bladder cancer	5.18e-05	0.000323	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SRC—urinary bladder cancer	5.1e-05	0.000318	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SRC—urinary bladder cancer	5.1e-05	0.000318	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.1e-05	0.000318	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	5.1e-05	0.000317	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CREBBP—urinary bladder cancer	4.98e-05	0.00031	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.82e-05	0.0003	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	4.79e-05	0.000298	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.75e-05	0.000296	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—UGT2B7—urinary bladder cancer	4.74e-05	0.000295	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—RRM2—urinary bladder cancer	4.68e-05	0.000292	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—urinary bladder cancer	4.61e-05	0.000287	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—urinary bladder cancer	4.61e-05	0.000287	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—urinary bladder cancer	4.57e-05	0.000285	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—urinary bladder cancer	4.57e-05	0.000285	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	4.56e-05	0.000284	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.55e-05	0.000283	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTO2—urinary bladder cancer	4.54e-05	0.000283	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAT1—urinary bladder cancer	4.54e-05	0.000283	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.49e-05	0.00028	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—urinary bladder cancer	4.47e-05	0.000279	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—urinary bladder cancer	4.47e-05	0.000279	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.43e-05	0.000276	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.41e-05	0.000274	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—EP300—urinary bladder cancer	4.4e-05	0.000274	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—EP300—urinary bladder cancer	4.4e-05	0.000274	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.37e-05	0.000272	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	4.34e-05	0.00027	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ENO2—urinary bladder cancer	4.34e-05	0.00027	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.31e-05	0.000269	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP4B1—urinary bladder cancer	4.27e-05	0.000266	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—urinary bladder cancer	4.23e-05	0.000263	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—urinary bladder cancer	4.23e-05	0.000263	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	4.21e-05	0.000262	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	4.18e-05	0.00026	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	4.15e-05	0.000259	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.14e-05	0.000258	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—urinary bladder cancer	4.08e-05	0.000254	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA2—urinary bladder cancer	4.07e-05	0.000253	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC19A1—urinary bladder cancer	4.03e-05	0.000251	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PRSS3—urinary bladder cancer	3.93e-05	0.000245	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.86e-05	0.00024	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.84e-05	0.000239	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.81e-05	0.000237	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.74e-05	0.000233	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.73e-05	0.000232	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—urinary bladder cancer	3.59e-05	0.000224	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—urinary bladder cancer	3.59e-05	0.000224	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—urinary bladder cancer	3.56e-05	0.000222	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.53e-05	0.00022	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.51e-05	0.000218	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NQO1—urinary bladder cancer	3.5e-05	0.000218	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.44e-05	0.000214	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—EP300—urinary bladder cancer	3.39e-05	0.000211	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.39e-05	0.000211	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.37e-05	0.00021	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.26e-05	0.000203	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.25e-05	0.000202	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.15e-05	0.000196	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMP—urinary bladder cancer	3.14e-05	0.000196	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.1e-05	0.000193	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.06e-05	0.000191	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.02e-05	0.000188	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.01e-05	0.000188	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.96e-05	0.000184	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.95e-05	0.000184	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	2.92e-05	0.000182	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAU—urinary bladder cancer	2.89e-05	0.00018	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAT2—urinary bladder cancer	2.84e-05	0.000177	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.82e-05	0.000176	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.8e-05	0.000174	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.8e-05	0.000174	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.75e-05	0.000171	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMS—urinary bladder cancer	2.71e-05	0.000169	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.7e-05	0.000168	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	2.68e-05	0.000167	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	2.68e-05	0.000167	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.64e-05	0.000165	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—urinary bladder cancer	2.57e-05	0.00016	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.56e-05	0.000159	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	2.52e-05	0.000157	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.52e-05	0.000157	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.49e-05	0.000155	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.49e-05	0.000155	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RRM2—urinary bladder cancer	2.45e-05	0.000153	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.38e-05	0.000148	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	2.37e-05	0.000147	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—urinary bladder cancer	2.35e-05	0.000147	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.3e-05	0.000144	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPGDS—urinary bladder cancer	2.27e-05	0.000141	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO2—urinary bladder cancer	2.27e-05	0.000141	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.26e-05	0.000141	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.22e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—urinary bladder cancer	2.2e-05	0.000137	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.18e-05	0.000136	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.17e-05	0.000135	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RHOA—urinary bladder cancer	2.15e-05	0.000134	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.15e-05	0.000134	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.12e-05	0.000132	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.06e-05	0.000128	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.99e-05	0.000124	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.99e-05	0.000124	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.93e-05	0.00012	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—urinary bladder cancer	1.92e-05	0.00012	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	1.84e-05	0.000115	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NQO1—urinary bladder cancer	1.83e-05	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—urinary bladder cancer	1.81e-05	0.000113	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.81e-05	0.000113	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.78e-05	0.000111	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.7e-05	0.000106	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EP300—urinary bladder cancer	1.62e-05	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.6e-05	9.99e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—urinary bladder cancer	1.58e-05	9.83e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.55e-05	9.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.53e-05	9.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—urinary bladder cancer	1.53e-05	9.51e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	1.51e-05	9.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.48e-05	9.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—urinary bladder cancer	1.42e-05	8.84e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—urinary bladder cancer	1.4e-05	8.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOR1—urinary bladder cancer	1.4e-05	8.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—urinary bladder cancer	1.34e-05	8.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	8.33e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.32e-05	8.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ERCC2—urinary bladder cancer	1.32e-05	8.21e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—urinary bladder cancer	1.32e-05	8.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—urinary bladder cancer	1.31e-05	8.14e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—EP300—urinary bladder cancer	1.26e-05	7.82e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.24e-05	7.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—urinary bladder cancer	1.24e-05	7.72e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	7.66e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	7.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.23e-05	7.63e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.23e-05	7.63e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.19e-05	7.4e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.18e-05	7.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—urinary bladder cancer	1.16e-05	7.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.16e-05	7.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—urinary bladder cancer	1.11e-05	6.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	6.77e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—urinary bladder cancer	1.01e-05	6.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.88e-06	6.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CREBBP—urinary bladder cancer	9.66e-06	6.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.81e-06	5.49e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.46e-06	5.27e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.24e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—urinary bladder cancer	7.91e-06	4.93e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.66e-06	4.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.57e-06	4.72e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.57e-06	4.72e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.25e-06	4.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.12e-06	4.43e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.93e-06	4.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—urinary bladder cancer	6.9e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.69e-06	4.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EP300—urinary bladder cancer	6.58e-06	4.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.04e-06	3.76e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EP300—urinary bladder cancer	5.76e-06	3.59e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.43e-06	3.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.21e-06	3.25e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.27e-06	2.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.72e-06	2.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.55e-06	2.21e-05	CbGpPWpGaD
